Explore the words cloud of the MACUSTAR project. It provides you a very rough idea of what is the project "MACUSTAR" about.
The following table provides information about the project.
|Coordinator Country||Germany [DE]|
|Total cost||16˙218˙917 €|
|EC max contribution||8˙025˙000 € (49%)|
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
|Duration (year-month-day)||from 2017-09-01 to 2022-08-31|
Take a look of project's partnership.
|1||UNIVERSITAETSKLINIKUM BONN||DE (BONN)||coordinator||3˙823˙388.00|
|2||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||participant||1˙033˙456.00|
|3||UNIVERSITY COLLEGE LONDON||UK (LONDON)||participant||782˙987.00|
|4||FONDATION DE COOPERATION SCIENTIFIQUE VOIR ET ENTENDRE||FR (PARIS)||participant||760˙639.00|
|5||MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST||UK (LONDON)||participant||552˙279.00|
|6||AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM||PT (COIMBRA)||participant||348˙024.00|
|7||CITY UNIVERSITY OF LONDON||UK (LONDON)||participant||280˙383.00|
|8||ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK||FR (PARIS)||participant||233˙161.00|
|9||THE UNIVERSITY OF SHEFFIELD||UK (SHEFFIELD)||participant||210˙679.00|
|10||BAYER AKTIENGESELLSCHAFT||DE (Leverkusen)||participant||0.00|
|11||CARL ZEISS MEDITEC AG||DE (JENA)||participant||0.00|
|12||F. HOFFMANN-LA ROCHE AG||CH (BASEL)||participant||0.00|
|13||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
Despite significant advances in the treatment and understanding of late stage age-related macular degeneration (AMD), it continues to be the main cause of irreversible severe visual loss in Europe and its prevalence and incidence will increase with current demographic trends. In order to reduce the significant burden of late stage AMD, novel interventions should aim at stopping or delaying progression from the preceding disease stage intermediate AMD (iAMD) to late stage AMD. As a prerequisite, validated clinical endpoints for iAMD are needed. These should be acceptable to regulatory agencies, health technology assessment (HTA) bodies, and payers. Currently such endpoints do not exist for iAMD clinical trials (CTs).
In addition, there is good evidence indicating that patients with iAMD experience some impairment of visual function yet it is unknown to what extend this impacts the patients’ life nor can it be reliably measured and quantified. It is also unknown whether there are specific risk factors in the population of iAMD patients which identify those with more rapid progression to late stages of the disease.
Therefore, to enable successful development of iAMD interventions validated functional, morphological and patient--reported endpoints for CTs, which are clinically meaningful and accepted by regulatory agencies, are required. In addition, functional decline in iAMD, as well as, specific risk factors for iAMD progression to late stage AMD need to be better characterized to inform and improve conduct of future iAMD CTs.
Against this background, the major objective of MACUSTAR is to develop novel clinical endpoints for CTs with a regulatory and patient access intention in patients with iAMD. Additional objectives are to characterize visual impairment in iAMD and its progression, as well as, identify risk factors for progression.
For clinical endpoint development, functional, structural and patient-reported outcome measures will be assessed with regards to
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MACUSTAR" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MACUSTAR" are provided by the European Opendata Portal: CORDIS opendata.